Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/28/2008

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 4, 2008 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

For
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
2. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. ThreeWire Expands Presence in the Pharmaceutical Arena
5. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
9. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
10. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...if.,Nov.24/PRNewswire/--Twomoreprestigiousuniversi...linejobboardandcareerssiteforlifescienceprofession...membersofthejobboard,joining28othermajorlifescienc...areercenter.com ,isonlyforpost-graduatesinthelifes...tesontheInternet,BioCareerCenteristheonlyonethatse...
(Date:11/24/2009)... Health care employment grew by 29,000 jobs ...show consistent growth during the U.S. recession. ... trouble, and health systems are coming closer to ...of just administrators. , ...nt continued growing in October despite the sheddi...
(Date:11/24/2009)...24/PRNewswire-Asia/--ShanghaiBiolaxyannouncedthe,C...rovedthe,investigationalnewdrugapplication(IND)for...formulationtotreatdiabetes.ThisIND,approvalallowsB..., Diabetesisadisordercharacteristicofhighbloodgluc...tenresultinseveremicro-and,macro-vasculardiseases,...
(Date:11/24/2009)...L , TORONTO,Nov.24/PRNewswire-FirstCall/-Hami...c.,aleadingproviderofadvancedlasersystemsandinstru...ts,todayreportedoperationalandfinancialresultsfort...hlights,-Revenuewas$1.46millioncomparedwith$1.43m...paredwith66.1percentinQ3,2008,-Netlossreducedto$14...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7
...uticals,Inc. (Nasdaq: ANDS ), a clinical-stage bi...ient care by developing novel medicines in the are... financial results and,highlights for the third qu...make rapid progress in both of our hepatitis C,dev...ident and CEO of,Anadys. "We completed our first c...
...all/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ... Phase I,Study to Evaluate Systemic Wild-Type Reov...n Patients with Advanced Malignancies" will be ava...al of Immunotherapy, the official,journal of the I...cer,(iSBTc). The principal investigator for the tr...
...ne today announced,that researchers will present e... at the Annual Meeting of the American College of ...oscone Center in San Francisco, California., "Med...ns for patients,struggling with systemic autoimmun...ice president, clinical development, respiratory,i...
Other Biology Technology:Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 8Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 3MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 2MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 3
(Date:11/23/2009)...des "incontrovertible evidence" that the volcanic ...out 73,000 years ago deforested much of central In...ers report. , The volcano ejected an estimated 8...aving a crater (now the world,s largest volcanic l... wide. Ash from the event has been found in India,...
(Date:11/23/2009)...USDOE and USDA study concluded that 50 million U.S...asture could be converted from current uses to the...ass, from which biomass could be harvested for use...ction of a perennial grass monoculture from which ...ally is expected to require nitrogen fertilizer. ,...
(Date:11/23/2009)...eal in unprecedented detail how the ribosome inter... and guide them toward their destination in biolog...exible fitting (MDFF) to examine the interaction o...rs. , The first study, in Proceedings of the N...e signaling between the ribosome and an elongation...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Switchgrass produces biomass efficiently 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 1Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 2Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 3Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 4Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 5Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 6Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 7Study Shows GSKs Novel Diabetes Treatment SYNCRIA 28R 29 28albiglutide 29 Improves Glucose Control and Reduces Weight 4549 1Study Shows GSKs Novel Diabetes Treatment SYNCRIA 28R 29 28albiglutide 29 Improves Glucose Control and Reduces Weight 4549 2Study Shows GSKs Novel Diabetes Treatment SYNCRIA 28R 29 28albiglutide 29 Improves Glucose Control and Reduces Weight 4549 3Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel 26amp 3B Thermage User Forum Held at Beckman Laser Institute 12498 1Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel 26amp 3B Thermage User Forum Held at Beckman Laser Institute 12498 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel 26amp 3B Thermage User Forum Held at Beckman Laser Institute 12498 3
... In recent years, a growing scarcity of energy com...ey geopolitical risks and threats, such as conflic...nalism. However, a study released this week by Ric...uggests that, taken individually, many of the risk...rophic than they seem at first glance. The executi...
... Fishery biologist Sandy Sutherland looks through ...h earbones, known as otoliths, each showing annual...o determine the age of the fish, then moves on to ...nd is one of a small team at NOAAs Northeast Fishe...itical to stock assessments needed to manage the n...
... This press release is available in German . , ...cost us in the long term" How much do national eco...nd" And what price will we have to pay if we do no...nomics of Ecosystems and Biodiversity - project is...ukhdev, who is head of Deutsche Bank,s Global Mark...
Other Biology News:Baker Institute study, conference weigh risks for global energy markets 2Saltwater sleuths: Seeking clues to help determine the ages of fish and shellfish populations 2Saltwater sleuths: Seeking clues to help determine the ages of fish and shellfish populations 3Saltwater sleuths: Seeking clues to help determine the ages of fish and shellfish populations 4Biodiversity as a natural resource 2
...llow 5-minute cloning and subsequent sequencing of...rs with primer sites located as close as 33 base p...imizes the amount of vector DNA that needs to be r...ctors are available. The pCR4-TOPO vector provides...
Transfer & Blot Paper from NuSep Ltd
Dynabeads M-450 Epoxy from Dynal Biotech
GIBCO Earles Balanced Salt Solution (EBSS) (1X); liquid from Invitrogen
Biology Products: